Myriad Genetics Inc. (MYGN)

35.87
NASDAQ : Health Technology
Prev Close 35.94
Day Low/High 35.58 / 36.09
52 Wk Low/High 19.75 / 41.57
Avg Volume 649.90K
Exchange NASDAQ
Shares Outstanding 69.91M
Market Cap 2.51B
EPS 0.30
P/E Ratio 112.31
Div & Yield N.A. (N.A)

Latest News

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Myriad Genetics, Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Myriad Genetics, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of purchasers of Myriad Genetics, Inc.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Myriad Genetics, Inc.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Myriad Genetics, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Myriad Genetics, Inc.

Myriad Genetics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Possible Breaches Of Fiduciary Duty By Officers And Directors

Myriad Genetics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, announces that a federal class action lawsuit has been filed against Myriad Genetics ("Myriad" or "Company") (NasdaqGS: MYGN) and...

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against Myriad Genetics, Inc. (MYGN) And June 19 Lead Plaintiff Deadline

Scott Scott Attorneys At Law LLP Reminds Investors Of Securities Class Action Against Myriad Genetics, Inc. (MYGN) And June 19 Lead Plaintiff Deadline

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Myriad Genetics, Inc.

The Klein Law Firm Reminds Investors Of A Class Action Commenced On Behalf Of Myriad Genetics, Inc. Shareholders And A Lead Plaintiff Deadline Of June 19, 2018

The Klein Law Firm Reminds Investors Of A Class Action Commenced On Behalf Of Myriad Genetics, Inc. Shareholders And A Lead Plaintiff Deadline Of June 19, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Myriad Genetics, Inc.

MYGN EQUITY ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Myriad Genetics, Inc. And A Lead Plaintiff Deadline Of June 19, 2018

MYGN EQUITY ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Myriad Genetics, Inc. And A Lead Plaintiff Deadline Of June 19, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of investors who purchased Myriad Genetics, Inc.

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Myriad Genetics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of June 19, 2018

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Myriad Genetics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of June 19, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Myriad Genetics, Inc.

MYGN Crosses Above Average Analyst Target

In recent trading, shares of Myriad Genetics, Inc. have crossed above the average analyst 12-month target price of $33.36, changing hands for $33.55/share.

The Klein Law Firm Announces A Class Action Commenced On Behalf Of Myriad Genetics, Inc. Shareholders And A Lead Plaintiff Deadline Of June 19, 2018

The Klein Law Firm Announces A Class Action Commenced On Behalf Of Myriad Genetics, Inc. Shareholders And A Lead Plaintiff Deadline Of June 19, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Myriad Genetics, Inc.

MYGN INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Myriad Genetics, Inc. And A Lead Plaintiff Deadline Of June 19, 2018

MYGN INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Myriad Genetics, Inc. And A Lead Plaintiff Deadline Of June 19, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of investors who purchased Myriad Genetics, Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Myriad Genetics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of June 19, 2018

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Myriad Genetics, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of June 19, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Myriad Genetics, Inc.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Myriad Genetics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Myriad Genetics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of purchasers of Myriad Genetics, Inc.

Kessler Topaz Meltzer & Check, LLP Announces Investor Class Action Lawsuit Filed Against Myriad Genetics, Inc.

Kessler Topaz Meltzer & Check, LLP Announces Investor Class Action Lawsuit Filed Against Myriad Genetics, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP announces that an investor class action lawsuit has been filed against Myriad Genetics, Inc.

MYGN LOSS NOTICE: Rosen Law Firm Reminds Myriad Genetics, Inc. Investors Of Important Deadline In Class Action - MYGN

MYGN LOSS NOTICE: Rosen Law Firm Reminds Myriad Genetics, Inc. Investors Of Important Deadline In Class Action - MYGN

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Myriad Genetics, Inc.

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Myriad Genetics, Inc.

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Myriad Genetics, Inc.

The Klein Law Firm announces the commencement of an investigation of Myriad Genetics, Inc.

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Myriad Genetics, Inc. (MYGN)

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Myriad Genetics, Inc. (MYGN)

The Klein Law Firm announces the commencement of an investigation of Myriad Genetics, Inc.

INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Myriad Genetics, Inc.

INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Myriad Genetics, Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Myriad Genetics, Inc.

TheStreet Quant Rating: C+ (Hold)